文献速递认知障碍与痴呆

多基因效应对阿尔茨海默病tau病理进展的影响

Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease.
PubMed 文献 · Ann Neurol · 2023-01-04

研究利用85个阿尔茨海默病(AD)先导单核苷酸多态性(SNP)构建多基因评分(PGS),在231名ADNI参与者中评估纵向tau-PET、淀粉样蛋白-PET和认知。发现较高PGS与tau-PET积累率较高相关,尤其在淀粉样蛋白-PET水平升高时,tau-PET增加介导PGS与更快认知下降的关联,高PGS风险富集使临床试验样本量节省34%。

要点

  • 较高PGS与tau-PET积累率较高相关,尤其在淀粉样蛋白-PET升高时。
  • tau-PET增加介导PGS与更快认知下降的关联。
  • 高PGS风险富集使靶向tau病理的临床试验样本量节省34%。

核心结论

  • PGS可预测更快的tau进展及认知下降,有助于提高临床试验的统计效能。

研究设计与样本

  • 研究结合近期全基因组关联研究(GWAS)中85个AD先导SNP构建PGS,在231名ADNI参与者中评估纵向tau-PET、淀粉样蛋白-PET和认知。

主要发现

  • 较高PGS与tau-PET积累率较高相关,尤其在淀粉样蛋白-PET水平升高时。
  • tau-PET增加介导PGS与更快认知下降的关联。
  • 高PGS风险富集使临床试验所需样本量节省34%。

关键数值与推荐

  • PGS基于85个AD先导SNP构建。
  • 高PGS风险富集使样本量节省34%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Polygenic variation accounts for a substantial portion of the risk of Alzheimer's disease (AD), but its effect on the rate of fibrillar-tau accumulation as a key driver of dementia symptoms is unclear. METHODS: We combined the to-date largest number of genetic risk variants of AD (n = 85 lead single-nucleotide polymorphisms [SNPs]) from recent genome-wide association studies (GWAS) to generate a polygenic score (PGS). We assessed longitudinal tau-positron emission tomography (PET), amyloid-PET, and cognition in 231 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Using the PGS, together with global amyloid-PET, we predicted the rate of tau-PET increases in Braak-stage regions-of-interest and cognitive decline. We also assessed PGS-risk enrichment effects on the required sample size in clinical trials targeting tau pathology. RESULTS: We found that a higher PGS was associated with higher rates of tau-PET accumulation, in particular at elevated amyloid-PET levels. The tau-PET increases mediated the association between PGS and faster cognitive decline. Risk enrichment through high PGS afforded sample size savings by 34%. INTERPRETATION: Our results demonstrate that the PGS predicts faster tau progression and thus cognitive decline, showing utility to enhance statistical power in clinical trials. ANN NEUROL 2023;93:819-829.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Rubinski A, Frerich S, Malik R, et al. Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease. Ann Neurol. 2023. PMID: 36571564. doi:10.1002/ana.26588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。